Nature Biotechnology Webcast on CAR-T Cells: Latest Advances and Outstanding Challenges

Date: 20 September 2017 Location: Online event City: Online event Country: Online event
lymphocytes attacking cancer cell
Wednesday, 20 September 2017

9 AM PDT (Los Angeles) / 12 PM EDT (New York) / 5 PM BST (London) / 6 PM CEST (Berlin) 

Presented by Nature Biotechnology, sponsored by Lonza

The efficacy of CAR-T cells in acute lymphoblastic leukemia has ignited the field, as researchers and clinicians move to advance the technology. T cells, obtained from the patient and engineered to express a chimeric antigen receptor (CAR) that mediates antigen recognition and cellular activation, can kill tumor cells within days. The approach promises to expand to a broad range of tumors and antigens, with dozens of clinical trials now ongoing and FDA approval expected soon.           


In recent months, ground has been gained towards identifying suitable target antigens beyond CD19, overcoming suppression in the microenvironment of solid tumors, and developing strategies to deal with antigen escape. Advances in clinical development, including efforts to develop a universal T cell line, identifying the best T cell subsets and managing side effects, will help reach patients outside a few academic centers. Looking beyond CAR-T cells, CAR-expressing NK and ϒδ T cells for cancer and CAAR-T cells for autoimmunity may represent promising approaches


Join this 60-minute free webcast and learn about the latest advances and outstanding challenges in the fast paced research environment of CARs with experts that bridge the lab and clinic.       


  • Marcela Maus, Assistant Professor, Harvard Medical School
  • Renier Brentjens, Associate Member, Memorial Sloan Kettering Cancer Center
  • Martin Pule, Clinical Senior Lecturer, University College London



The second half of the webcast will be a live Q&A, offering you a chance to pose questions to the expert panelists.

Register now 

Unable to join?

Register now and receive a notification once the webcast is available for on-demand viewing.